on December 2, 2002
Published online before print December 2, 2002, doi: 10.1161/01.HYP.0000047512.58862.A9
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 12, 2002
From the Division of Hypertensive and Vascular Medicine, University Hospital of Lausanne, Switzerland. * To whom correspondence should be addressed. E-mail: Michel.Burnier{at}chuv.hospvd.ch.
Abstract—We assessed the blockade of the renin-angiotensin system (RAS) achieved with 2 angiotensin (Ang) antagonists given either alone at different doses or with an ACE inhibitor. First, 20 normotensive subjects were randomly assigned to 100 mg OD losartan (LOS) or 80 mg OD telmisartan (TEL) for 1 week; during another week, the same doses of LOS and TEL were combined with 20 mg OD lisinopril. Then, 10 subjects were randomly assigned to 200 mg OD LOS and 160 mg OD TEL for 1 week and 100 mg BID LOS and 80 mg BID TEL during the second week. Blockade of the RAS was evaluated with the inhibition of the pressor effect of exogenous Ang I, an ex vivo receptor assay, and the changes in plasma Ang II. Trough blood pressure response to Ang I was blocked by 35±16% (mean±SD) with 100 mg OD LOS and by 36±13% with 80 mg OD TEL. When combined with lisinopril, blockade was 76±7% with LOS and 79±9% with TEL. With 200 mg OD LOS, trough blockade was 54±14%, but with 100 mg BID it increased to 77±8% (P<0.01). Telmisartan (160 mg OD and 80 mg BID) produced a comparable effect. Thus, at their maximal recommended doses, neither LOS nor TEL blocks the RAS for 24 hours; hence, the addition of an ACE inhibitor provides an additional blockade. A 24-hour blockade can be achieved with an angiotensin antagonist alone, provided higher doses or a BID regimen is used.
Revised on September 7, 2002
Angiotensin II Receptor Blockade. Is There Truly a Benefit of Adding an ACE Inhibitor?
Andrei Forclaz;
Key words: angiotensin II • receptors, angiotensin • angiotensin-converting enzyme • human • telmisartan • losartan
This article has been cited by other articles:
 |
|
 |
|
  J. Redon and M. J. Fabia Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan Journal of Renin-Angiotensin-Aldosterone System, September 1, 2009; 10(3): 147 - 156. [Abstract] [PDF]
|
|
|
|
|
|
T. Berl Review: Renal protection by inhibition of the renin-angiotensin-aldosterone system Journal of Renin-Angiotensin-Aldosterone System, March 1, 2009; 10(1): 1 - 8. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Berl Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2443 - 2447. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Huang, C. Xu, K. W. Kahng, N. A. Noble, W. A. Border, and Y. Huang Aldosterone and TGF-{beta}1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1287 - F1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Linas Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(Supplement_1): S17 - S23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Burnier Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 208 - 211. [PDF]
|
|
|
|
 |
|
 S. G. Tsouli, E. N. Liberopoulos, D. N. Kiortsis, D. P. Mikhailidis, and M. S. Elisaf Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 1 - 15. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M.A. van de Wal, D. J. van Veldhuisen, W. H. van Gilst, and A. A. Voors Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J., November 2, 2005; 26(22): 2361 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W.R. Doulton, F. J. He, and G. A. MacGregor Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension Hypertension, May 1, 2005; 45(5): 880 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azizi, J. Menard, A. Bissery, T.-T. Guyenne, A. Bura-Riviere, S. Vaidyanathan, and R. P. Camisasca Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3126 - 3133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azizi and J. Menard Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists Circulation, June 1, 2004; 109(21): 2492 - 2499. [Full Text] [PDF]
|
|
|
|
|
|
M. Azizi, A. Bissery, M. Lamarre-Cliche, and J. Menard Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans Hypertension, April 1, 2004; 43(4): 785 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Segura, M. Praga, C. Campo, J. L Rodicio, and L. M Ruilope Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 43 - 47. [Abstract] [PDF]
|
|